

Ashwini Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1107699/publications.pdf>

Version: 2024-02-01

15
papers

373
citations

1305906

8
h-index

1181555

14
g-index

15
all docs

15
docs citations

15
times ranked

720
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	7.7	73
2	Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1212.	1.7	5
3	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. <i>Scientific Reports</i> , 2021, 11, 23565.	1.6	6
4	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2780-2784.	3.3	6
5	Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 546-559.	2.5	36
6	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 708-720.	1.7	99
7	Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia. <i>Scientific Reports</i> , 2019, 9, 11796.	1.6	9
8	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. <i>Leukemia</i> , 2019, 33, 2548-2553.	3.3	25
9	Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. <i>Cancer Research</i> , 2019, 79, 2466-2479.	0.4	23
10	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1360-1372.	3.3	40
11	Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 725-732.	0.6	5
12	The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. <i>BMC Genomics</i> , 2017, 18, 629.	1.2	42
13	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854.	0.6	1
14	DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors. <i>Blood</i> , 2016, 128, 198-198.	0.6	0
15	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. <i>Blood</i> , 2014, 124, 2203-2203.	0.6	3